Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
Status:
Completed
Trial end date:
2017-12-19
Target enrollment:
Participant gender:
Summary
This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after
the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain
eligible for continued treatment with androgen deprivation therapy. Subjects participating in
Protocol FP01C-13-001-EX will be followed for safety only.